Clinical study of rapid remission of gastroesophageal reflux-induced chronic cough by gabapentin

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR1800017944

Enrollment

Unknown

Registered

2018-08-24

Start date

2018-09-01

Completion date

Unknown

Last updated

2018-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastroesophageal reflux-induced chronic cough

Interventions

Group 1:gabapentin+standard therapy

Group 2:placebo+standard therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Age from 18 to 70 years old; 2. cough more than 8 weeks, and normal chest imaging, with or without typical reflux symptom like acid regurgitation, heartburn, and retrosternal pain; 3. DeMeester=12.70 and/or SAP=80% in MII-pH; 4. UACS, CVA, and EB are excluded, or cough cannot be cured or remitted by etiological treatment.

Exclusion criteria

Exclusion criteria: 1. women with pregnancy or lactation, patients refusing to sign the informed consent; 2. smoker or former smoker within two years; 3. patients using PPI, gastric motility stimulant, or gabapentin within 2 monts; 4. respiratory tract infection within 8 weeks; 5. unsuitable situations confirmed by researchers; 6. contraindication of gabapentin.

Design outcomes

Primary

Measure	Time frame
Cough symptom score;LCQ;GerdQ;HARQ;capsaicine cough threshold;lung function test;bronchial provocation test;MII-pH;	—

Countries

China

Contacts

Public ContactZhongmin Qiu

Shanghai Tongji Hospital

qiuzhongmin@tongji.edu.cn+86 13671892140

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026